coagulation monitoring
MedApps is providing a revolutionary change to the way Coumadin or warfarin patients analyze their blood coagulation levels. Historically, patients on blood thinning medication have needed to travel to hospitals or Coumadin clinics for PT testing.
With over 2 million new people taking anticoagulation medication every year to prevent blood clots, stroke, and heart attacks – the need for careful monitoring of these users has never been greater, and correct medication dosing is important to assure the best outcomes for these patients.
MedApps allows these individuals the ability to test PT levels from the comfort of their home and avoid the need to travel for this analysis. Further, it has been demonstrated that patients who self-test, test in their “safe-zone” or therapeutic range 56% of the time – versus a 32% rate for patients receiving typical testing. A ten-year study of the ESCAT (Early Self-Controlled Anticoagulation Test) showed a 33% increased survival rate for self-testing patients over conventional therapy.
Current reimbursement is available for PT/INR testing under CMS for coagulation monitoring, including $10/week for professionals to review, $150/mo for supplies, including equipment and connectivity and $150 for training.
MedApps is scheduled to deliver the first remote transmission system for PT/INR data in the industry by Q4 2011 under IRB, pending FDA clearance.
Partnering with Other Innovators
in Remote Health Monitoring
MedApps coagulation monitoring kits, for use with the Abbott PT/INR monitor will be available in Q1 of 2012 pending FDA clearance. Learn more about Coagusense.Related Articles
Self-Management of Oral Anticoagulation Therapy Improves Long-Term SurvivalAnnals of Thoracic Surgery
